Core Insights - INBRAIN Neuroelectronics has announced a strategic collaboration with Microsoft to enhance agentic AI for precision neurology and brain-computer interface (BCI) therapeutics [1][2] - The partnership aims to utilize Microsoft's Azure AI infrastructure to enable INBRAIN's platform to learn and adapt to individual patient signals in real time [2][3] - This collaboration is expected to transform the monitoring and treatment of neurological disorders, offering closed-loop precision interventions for conditions like Parkinson's disease and epilepsy [2][3] Company Overview - INBRAIN Neuroelectronics is pioneering real-time precision neurology with the world's first graphene-based BCI therapeutics platform [5] - The technology combines precise BCI decoding with micrometric modulation to provide adaptive, personalized treatments for various neurological conditions [5] - The platform aims to maximize therapeutic outcomes while minimizing side effects through continuous real-time monitoring and autonomous therapy adjustments [5] Technological Advancements - The collaboration will integrate advanced decoding and modulation with agentic AI, enabling personalized, data-driven modulation of neural circuits in real time [3] - INBRAIN's neural platform is built on graphene, known for its exceptional conductivity and biocompatibility, which enhances the effectiveness of BCI therapeutics [3][4] - The partnership underscores a commitment to ethical innovation and patient privacy in neurotechnology development [4]